

INFORMATION ONLY

Introduction of HyQvia

Customer Letter # 2023-27

2023-10-16

Dear Colleagues:

Canadian Blood Services is pleased to announce **Normal Immunoglobulin (Human) 10% and Recombinant Human Hyaluronidase (HyQvia)** will be listed on the Canadian Blood Services formulary as a replacement therapy for primary humoral immunodeficiency (PI) and secondary humoral immunodeficiency (SI) in adult patients.

HyQvia will be available for hospital customers to order by **December 4th, 2023**.

Key Product Highlights:

See the table below for available vial sizes

- Storage temperature: +2°C to +8°C
- Route of administration: Subcutaneous

Product	Material Master Number	Normal Immunoglobulin (Human) 10% vial	Recombinant Human Hyaluronidase vial
HyQvia 2.5 g	1000109376	2.5 g/25 mL	200 U/1.25 mL
HyQvia 5 g	1000109377	5 g/50 mL	400 U/2.5 mL
HyQvia 10 g	1000109378	10 g/100 mL	800 U/5 mL
HyQvia 20 g	1000109379	20 g/200 mL	1600 U/10 mL
HyQvia 30 g	1000109380	30 g/300 mL	2400 U/15 mL

Please see the sponsor's letter for additional information.

The following forms will be updated by December 4th, 2023, and posted on www.blood.ca.

- Volume Expanders/Immune Globulins and S/D Plasma Order Form
- Plasma Protein and Related Products – Customer Table of Information

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospital Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier
Director, Plasma Protein and Related Products Formulary Program